Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial)

INTRODUCTION: Misfolded aggregated proteins and neuroinflammation significantly contribute to amyotrophic lateral sclerosis (ALS) pathogenesis, hence representing therapeutic targets to modify disease expression. Rapamycin inhibits mechanistic target of Rapamycin (mTOR) pathway and enhances autophag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Mandrioli, Jessica, D’Amico, Roberto, Zucchi, Elisabetta, Gessani, Annalisa, Fini, Nicola, Fasano, Antonio, Caponnetto, Claudia, Chiò, Adriano, Dalla Bella, Eleonora, Lunetta, Christian, Mazzini, Letizia, Marinou, Kalliopi, Sorarù, Gianni, de Biasi, Sara, Lo Tartaro, Domenico, Pinti, Marcello, Cossarizza, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6024184/
https://ncbi.nlm.nih.gov/pubmed/29901635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011119
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados